Development of a Therapeutic mRNA HPV Vaccine using Phion's Delivery Technology

感染人乳头瘤病毒(HPV)会导致生殖器疣、癌前病变和癌症。HPV是最常见的性传播疾病，但目前所有的疫苗都是为预防这种疾病而设计的，目前还没有有效的治疗方法来治疗目前感染的人。鉴于全球目前有2亿人感染HPV，显然需要创造一种能够治疗这种疾病并清除感染的疫苗，这是该项目的主要重点。要使疫苗具有治疗作用，需要一种特殊类型的免疫，称为CD8反应。Phion治疗公司已经开发出一种能产生CD8反应的疫苗。我们之所以得到这种反应，是因为我们可以使用穿透性多肽作为递送载体，将疫苗输送到正确的细胞中。我们是唯一一家拥有这种多肽来交付疫苗的公司。疫苗本身是一种基因货物(MRNA)，旨在对特定疾病的抗原进行编码。到目前为止，我们已经生产并公布了数据，证明我们的原型疫苗可以消除体内的目标感染细胞。该项目旨在使用名为E6/E7的基因信使核糖核酸抗原构建一种专门针对HPV的疫苗。我们的目标是从疾病的小动物和大动物模型中清除HPV感染。我们还将收集关于最佳剂量和何时接种疫苗的关键信息，以获得最佳治疗反应。我们的愿景是将我们的技术带到管道上，这样到最后我们就可以开始大规模的毒理学研究了。从这个项目中获得的数据包对于我们为这些毒理学研究筹集更多资金是至关重要的，这也是Phion内部项目管道成功的关键。这是一个高度创新的项目，因为它是第一个可用于治疗HPV的多肽/信使核糖核酸疫苗。此外，该项目的关键信息可用于制造针对单纯疱疹病毒(HSV)和人类免疫缺陷病毒(HIV)等病毒感染的治疗性疫苗。该项目中技术的发展可能会成为新一代疫苗的催化剂，这些疫苗旨在全球范围内清除病毒感染。

Infection with the human papilloma virus (HPV) leads to genital warts, pre-cancerous lesions and cancer. HPV is the most common sexually transmitted disease, yet all current vaccines are designed to prevent the disease and there is no effective treatment for those currently infected. Given that worldwide there are 200 million currently infected with HPV there is a clear need to create a vaccine that can treat the disease and clear the infection and that is the main focus of this project.To make a vaccine therapeutic a particular type of immunity is required known as a CD8+ response. Phion Therapeutics have created a vaccine that produces a CD8+ response. We get this response because we can deliver the vaccine into the correct cells using a cell penetrating peptide as a delivery vehicle. We are the only company to have this peptide to deliver the vaccine. The vaccine itself is a genetic cargo (mRNA) designed to code for the antigens in a particular disease.To date, we have produced and published data proving our prototype vaccine can eradicate target infected cells in vivo. This project is designed to build a vaccine specifically for HPV using genetic mRNA antigens termed E6/E7. We aim to clear HPV infections from small and large animal models of disease. We will also gather key information on the best dose and when to give the vaccine to get the best therapeutic response. The vision is to take our technology along the pipeline so that by the end we are ready to commence large-scale toxicology studies. The data pack achieved from this project is essential for us to raise further funds for these toxicology studies and this is also critical for the success of Phion's internal pipeline of projects. This is a highly innovative project as the first of its kind peptide/mRNA vaccine that can be used to treat HPV. Additionally, key information from this project can be applied to build therapeutic vaccines for viral infections such as Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV). The development of the technology in this project could be the catalyst for a new generation of vaccines designed to clear viral infections on a global scale.